{"id":"https://openalex.org/W2531464322","doi":"https://doi.org/10.1200/jco.2004.22.14_suppl.7554","title":"Phase II trial of karenitecin (BNP1350) in malignant: Clinical and translational study","display_name":"Phase II trial of karenitecin (BNP1350) in malignant: Clinical and translational study","publication_year":2004,"publication_date":"2004-07-15","ids":{"openalex":"https://openalex.org/W2531464322","doi":"https://doi.org/10.1200/jco.2004.22.14_suppl.7554","mag":"2531464322"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2004.22.14_suppl.7554","doi":"https://doi.org/10.1200/jco.2004.22.14_suppl.7554","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2004.22.14_suppl.7554","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5110235127","display_name":"Fredrick H. Hausheer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]},{"id":"https://openalex.org/I4210126566","display_name":"BioNumerik (United States)","ror":"https://ror.org/02yq66p71","country_code":"US","type":"company","lineage":["https://openalex.org/I4210126566"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"F. H. Hausheer","raw_affiliation_strings":["BioNumerik Pharmaceuticals, Inc., San Antonio, TX; H Lee Moffitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BioNumerik Pharmaceuticals, Inc., San Antonio, TX; H Lee Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854","https://openalex.org/I4210126566"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085328645","display_name":"Elmer Berghorn","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]},{"id":"https://openalex.org/I4210126566","display_name":"BioNumerik (United States)","ror":"https://ror.org/02yq66p71","country_code":"US","type":"company","lineage":["https://openalex.org/I4210126566"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"E. Berghorn","raw_affiliation_strings":["BioNumerik Pharmaceuticals, Inc., San Antonio, TX; H Lee Moffitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BioNumerik Pharmaceuticals, Inc., San Antonio, TX; H Lee Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854","https://openalex.org/I4210126566"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031907118","display_name":"Z. Liu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]},{"id":"https://openalex.org/I4210126566","display_name":"BioNumerik (United States)","ror":"https://ror.org/02yq66p71","country_code":"US","type":"company","lineage":["https://openalex.org/I4210126566"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Z. Liu","raw_affiliation_strings":["BioNumerik Pharmaceuticals, Inc., San Antonio, TX; H Lee Moffitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BioNumerik Pharmaceuticals, Inc., San Antonio, TX; H Lee Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854","https://openalex.org/I4210126566"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102841436","display_name":"Daniel M. Sullivan","orcid":"https://orcid.org/0009-0003-0951-9781","observed_orcids":["https://orcid.org/0009-0003-0951-9781","https://orcid.org/0000-0002-2183-1773"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]},{"id":"https://openalex.org/I4210126566","display_name":"BioNumerik (United States)","ror":"https://ror.org/02yq66p71","country_code":"US","type":"company","lineage":["https://openalex.org/I4210126566"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"D. Sullivan","raw_affiliation_strings":["BioNumerik Pharmaceuticals, Inc., San Antonio, TX; H Lee Moffitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BioNumerik Pharmaceuticals, Inc., San Antonio, TX; H Lee Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854","https://openalex.org/I4210126566"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007883302","display_name":"Barbara Ann Centeno","orcid":"https://orcid.org/0009-0007-7668-2748","observed_orcids":["https://orcid.org/0009-0007-7668-2748"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]},{"id":"https://openalex.org/I4210126566","display_name":"BioNumerik (United States)","ror":"https://ror.org/02yq66p71","country_code":"US","type":"company","lineage":["https://openalex.org/I4210126566"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"B. Centeno","raw_affiliation_strings":["BioNumerik Pharmaceuticals, Inc., San Antonio, TX; H Lee Moffitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BioNumerik Pharmaceuticals, Inc., San Antonio, TX; H Lee Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854","https://openalex.org/I4210126566"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061930252","display_name":"J. Derderian","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]},{"id":"https://openalex.org/I4210126566","display_name":"BioNumerik (United States)","ror":"https://ror.org/02yq66p71","country_code":"US","type":"company","lineage":["https://openalex.org/I4210126566"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. Derderian","raw_affiliation_strings":["BioNumerik Pharmaceuticals, Inc., San Antonio, TX; H Lee Moffitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BioNumerik Pharmaceuticals, Inc., San Antonio, TX; H Lee Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854","https://openalex.org/I4210126566"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012013052","display_name":"Ronald C. DeConti","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]},{"id":"https://openalex.org/I4210126566","display_name":"BioNumerik (United States)","ror":"https://ror.org/02yq66p71","country_code":"US","type":"company","lineage":["https://openalex.org/I4210126566"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R. Deconti","raw_affiliation_strings":["BioNumerik Pharmaceuticals, Inc., San Antonio, TX; H Lee Moffitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BioNumerik Pharmaceuticals, Inc., San Antonio, TX; H Lee Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854","https://openalex.org/I4210126566"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018322482","display_name":"ADIL I. DAUD","orcid":"https://orcid.org/0000-0002-6617-8421","observed_orcids":["https://orcid.org/0000-0002-6617-8421"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]},{"id":"https://openalex.org/I4210126566","display_name":"BioNumerik (United States)","ror":"https://ror.org/02yq66p71","country_code":"US","type":"company","lineage":["https://openalex.org/I4210126566"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A. Daud","raw_affiliation_strings":["BioNumerik Pharmaceuticals, Inc., San Antonio, TX; H Lee Moffitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BioNumerik Pharmaceuticals, Inc., San Antonio, TX; H Lee Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854","https://openalex.org/I4210126566"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109265219","display_name":"Patricia Sullivan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]},{"id":"https://openalex.org/I4210126566","display_name":"BioNumerik (United States)","ror":"https://ror.org/02yq66p71","country_code":"US","type":"company","lineage":["https://openalex.org/I4210126566"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"P. Sullivan","raw_affiliation_strings":["BioNumerik Pharmaceuticals, Inc., San Antonio, TX; H Lee Moffitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BioNumerik Pharmaceuticals, Inc., San Antonio, TX; H Lee Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854","https://openalex.org/I4210126566"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5016816755","display_name":"Stephanie Andrews","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]},{"id":"https://openalex.org/I4210126566","display_name":"BioNumerik (United States)","ror":"https://ror.org/02yq66p71","country_code":"US","type":"company","lineage":["https://openalex.org/I4210126566"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S. Andrews","raw_affiliation_strings":["BioNumerik Pharmaceuticals, Inc., San Antonio, TX; H Lee Moffitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BioNumerik Pharmaceuticals, Inc., San Antonio, TX; H Lee Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854","https://openalex.org/I4210126566"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"22","issue":"14_suppl","first_page":"7554","last_page":"7554"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.9945999979972839,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.9945999979972839,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.002300000051036477,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/camptothecin","display_name":"camptothecin","score":0.8769999742507935},{"id":"https://openalex.org/keywords/metastatic-melanoma","display_name":"metastatic melanoma","score":0.9879999756813049},{"id":"https://openalex.org/keywords/topoisomerase-i","display_name":"topoisomerase I","score":0.9089999794960022},{"id":"https://openalex.org/keywords/topoisomerase-ii-alpha","display_name":"TOP2A","score":0.921999990940094},{"id":"https://openalex.org/keywords/topoisomerase-ii-beta","display_name":"topoisomerase II beta","score":1.0},{"id":"https://openalex.org/keywords/myelosuppression","display_name":"myelosuppression","score":0.8330000042915344},{"id":"https://openalex.org/keywords/drug-toxicity","display_name":"drug toxicity","score":0.5910000205039978},{"id":"https://openalex.org/keywords/tumor-response","display_name":"tumor response","score":0.5260000228881836},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.5559999942779541}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9187350273132324},{"id":"https://openalex.org/C147897179","wikidata":"https://www.wikidata.org/wiki/Q407828","display_name":"Topoisomerase","level":3,"score":0.7022281885147095},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.6977607607841492},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.5480312705039978},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5239070653915405},{"id":"https://openalex.org/C2775934546","wikidata":"https://www.wikidata.org/wiki/Q179991","display_name":"Biopsy","level":2,"score":0.46966660022735596},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4503624439239502},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.44521552324295044},{"id":"https://openalex.org/C2779682216","wikidata":"https://www.wikidata.org/wiki/Q419964","display_name":"Camptothecin","level":2,"score":0.4369655251502991},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.4301307499408722},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.42915016412734985},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.40421825647354126},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3958866000175476},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.06643807888031006},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.0},{"id":"https://openalex.org/C178790620","wikidata":"https://www.wikidata.org/wiki/Q11351","display_name":"Organic chemistry","level":1,"score":0.0}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1200/jco.2004.22.14_suppl.7554","doi":"https://doi.org/10.1200/jco.2004.22.14_suppl.7554","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2004.22.14_suppl.7554","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},{"id":"doi:10.1200/jco.2004.22.90140.7554","doi":"https://doi.org/10.1200/jco.2004.22.90140.7554","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2004.22.90140.7554","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2129938902","https://openalex.org/W2105590681","https://openalex.org/W2140103101","https://openalex.org/W2048838221","https://openalex.org/W2591018825","https://openalex.org/W1826133209","https://openalex.org/W1952453258","https://openalex.org/W7100745724","https://openalex.org/W2317278167","https://openalex.org/W2406150751"],"abstract_inverted_index":{"7554":[0],"Background:":[1],"To":[2],"determine":[3,119],"the":[4,9,22,120,194,302],"efficacy":[5],"and":[6,19,30,53,89,114,134,145,207,210,216,227,243,263],"safety":[7],"of":[8,24,26,43,60,65,68,138,184,193,220,287,304],"novel":[10],"camptothecin,":[11],"karenitecin":[12,69],"(BNP1350),":[13],"in":[14,222,229,253,266,278,301],"patients":[15,38,128,139,195,305],"with":[16,46,75,159,269,299,313],"metastatic":[17,44,279],"melanoma":[18,45,282],"to":[20,48,105,118,149,215,292],"measure":[21],"level":[23],"expression":[25,122,209,236,298],"topoisomerase":[27,121,241,244,288,297],"I,":[28,205,289],"II\u03b1":[29,206],"II\u03b2":[31,208,242],"through":[32],"directed":[33],"patient":[34,176],"biopsy.":[35],"Methods:":[36],"Eligible":[37],"had":[39,141,177,196],"a":[40,61,178,249],"histopathological":[41],"diagnosis":[42],"up":[47],"3":[49,79,117,200,219],"prior":[50,55,214],"chemotherapy":[51,150,221],"regimens":[52],"any":[54],"immunotherapy":[56],"regimens.":[57],"Treatment":[58],"consisted":[59],"60-minute":[62],"intravenous":[63],"infusion":[64],"1":[66],"mg/m2":[67],"daily":[70],"for":[71,84,131],"5":[72],"consecutive":[73],"days":[74],"cycles":[76,88],"repeated":[77],"every":[78,86],"weeks.":[80],"Patients":[81],"were":[82,111,129,189,212,260],"evaluated":[83],"progression":[85],"2":[87,256],"continued":[90],"on":[91,115,217],"treatment":[92],"ifthey":[93],"experienced":[94],"clinical":[95],"benefit":[96],"as":[97],"evidenced":[98],"by":[99,240],"stable":[100],"disease":[101,144,197],"or":[102,164,202,319,322],"objective":[103],"response":[104,133,180,300],"therapy.":[106,185],"Fine":[107],"needle":[108],"aspiration":[109],"biopsies":[110],"performed":[112],"pre-treatment":[113],"Day":[116,218],"from":[123],"patients'":[124],"tumors.":[125],"Results:":[126],"Forty-three":[127],"evaluable":[130],"tumor":[132,225],"toxicity.":[135],"The":[136,166],"majority":[137],"(72%)":[140],"stage":[142],"M1C":[143],"was":[146,156,171,237,248],"previously":[147],"exposed":[148],"(56%).":[151],"This":[152],"investigational":[153,251],"new":[154],"drug":[155],"well":[157],"tolerated":[158],"limited":[160],"GI":[161],"side":[162,258],"effects":[163,259],"fatigue.":[165],"major":[167],"dose-limiting":[168],"toxicity":[169],"observed":[170],"reversible":[172],"non-cumulative":[173],"myelosuppression.":[174],"One":[175],"complete":[179],"after":[181],"11":[182],"months":[183,201],"No":[186],"partial":[187],"responses":[188],"noted,":[190],"but":[191],"33%":[192],"stabilization":[198],"lasting":[199],"longer.":[203],"Topoisomerase":[204,234],"localization":[211],"determined":[213],"13":[223],"paired":[224],"samples,":[226],"pre-":[228],"an":[230],"additional":[231],"7":[232],"patients.":[233],"I":[235],"highest,":[238],"followed":[239],"II\u03b1.":[245],"Conclusions:":[246],"Karenitecin":[247,274],"well-tolerated":[250],"agent":[252],"this":[254,267,314],"Phase":[255],"study;":[257],"generally":[261],"mild":[262],"mostly":[264],"hematological":[265],"population":[268],"largely":[270],"adverse":[271],"prognostic":[272],"factors.":[273],"has":[275],"moderate":[276],"activity":[277],"melanoma.":[280],"While":[281],"metastases":[283],"express":[284],"high":[285],"levels":[286],"there":[290],"appears":[291],"be":[293],"no":[294],"correlation":[295],"between":[296],"subset":[303],"that":[306],"underwent":[307],"biopsies.":[308],"Further":[309],"studies":[310],"are":[311],"planned":[312],"agent.":[315],"Author":[316],"Disclosure":[317],"Employment":[318],"Leadership":[320],"Consultant":[321],"Advisory":[323],"Stock":[324],"Ownership":[325],"Honoraria":[326],"Research":[327],"Funding":[328],"Expert":[329],"Testimony":[330],"Other":[331],"Remuneration":[332],"BioNumerik":[333,336,339],"Pharmaceuticals,":[334,337,340],"Inc.":[335,338,341]},"counts_by_year":[],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2016-10-21T00:00:00"}